Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06862869 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Name: Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy — clinical trial record (NCT06862869)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseNot specified

SponsorHoffmann-La Roche

Started2025-04-30

View on ClinicalTrials.gov ↗

This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.

Amendment history 3 changes detected by DataLookout

2026-09-09

Primary completion pushed: 2028-10-30 → 2029-10-30

2026-09-09

Completion pushed: 2029-04-30 → 2030-02-28

2026-04-07

Trial sites expanded: 36 → 40 locations

Trial Details

NCT Number	NCT06862869
Lead Sponsor	Hoffmann-La Roche
Conditions	Carcinoma, Non-Small-Cell Lung
Enrollment	800 participants
Start Date	2025-04-30
Primary Completion	2029-10-30 (estimated)
Study Completion	2030-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-09-08